


**Sustained effectiveness and safety of subcutaneous tocilizumab over two years in an observational study (ARATA)**

**Supplementary Table S1.** Comparison of baseline demographics and key outcomes between the ARATA (TCZ-SC; n=1300 for safety set and n=1204 for effectiveness set) and ICHIBAN (TCZ-IV; n=3164 for safety set; n=2902 for effectiveness set) studies (reference 1, data on file). The data are from two independent studies.


Characteristic	ICHIBAN TCZ-IV		ARATA TCZ-SC	
	Baseline	Week 104	Baseline	Week 104
Demographics				
Age, mean (SD)	55.5 (13.1)	NA	57.3 (12.5)	NA
Female, %	74.8	NA	74.7	NA
RA disease duration, median	7	NA	7	NA
bDMARD naïve, %	30.0%	NA	36.7%	NA
Disease activity				
DAS28-ESR, mean (SD)	5.0 (1.5)	2.3 (1.4)	4.9 (1.3)	2.5 (1.4)
DAS28-ESR <2.6, %	3.6%	~60%*	4.8%	58.7%
DAS28-ESR ≤3.2, %	<10%*	77.9%	10.7%	72.7%
CDAI, mean (SD)	26.5 (13.6)	8.72 (9.72)	25.1 (11.6)	8.6 (9.3)
CDAI ≤2.8	<1%*	~30%*	0.5%	31.4%
CDAI ≤10	<10%*	~72%*	6.4%	70.8%
HAQ-DI, mean (SD)	1.3 (0.7)	0.9 (0.8)	1.2 (0.7)	0.9 (0.7)
HAQ-DI <0.5	NR	38.7%	20.3%	26.9%

bDMARD: biologic disease-modifying anti-rheumatic drugs; CDAI: Clinical Disease Activity Index; DAS28-ESR: Disease Activity Score based on 28 joints and erythrocyte sedimentation rate; HAQ-DI: Health Assessment Questionnaire-Disability Index; IV: intravenous; NA: not applicable; NR: not reported; RA: rheumatoid arthritis; SC: subcutaneous; SD: standard deviation; TCZ: tocilizumab.

\*Data extrapolated from graphs (exact percentages not reported).



**Supplementary Fig. S1.** DAS28-d<sub>crut</sub> responses (DAS28 improvement of ≥1.8 from baseline) in bDMARD-naïve vs. bDMARD-experienced patients over 2 years. bDMARD: biologic disease-modifying anti-rheumatic drugs.



**Supplementary Fig. S2.** Patient responses to questions concerning whether they (A) were satisfied with TCZ-SC; (B) felt restricted by TCZ-SC; and (C) would recommend TCZ-SC to other patients. Percentages may not total 100% due to rounding.

#### Supplementary reference

1. SPECKER C, ALBERDING A, ARINGER M *et al.*: ICHIBAN, a non-interventional study evaluating tocilizumab long-term effective-

ness and safety in patients with active rheumatoid arthritis. *Clin Exp Rheumatol* 2021; 39(2): 319-28. <https://doi.org/10.55563/clinexprheumatol/3qdgil>